Gene amplification and missense mutations activate FOXA1 and are reported in 6% and 10% primary and metastatic ER+ tumors, respectively70, resulting in genome-wide enhancer reprogramming in endocrine-resistant breast cancer cells. This evidence concerns the gene FOXA1 and breast cancer.